Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients.
In the past decade Direct Oral Anti-Coagulants (DOACs), targeting Thrombin or Factor Xa, have enormously facilitated the daily treatment of all relevant patients, including those requiring lifelong therapy. These DOACs have considerable advantages over the use of oral Vitamin K Antagonist (VKA) treatments, in view of having little interferences with food and other medications and also not requiring adjustment for age, gender or weight, with some well-defined exceptions. In this current What's Happening Section we focus on measurements of DiXaIs in plasma using anti-Xa assays, with the objective of providing a tribute to Professor Michel Meyer Samama, who was not only a real leader in this field but, in the past, both authors benefited from his wisdom, as a teacher who dedicated his scientific and professional life (among many other interests in hemostasis, thrombosis and fibrinolysis) to develop and promote methods and strategies for laboratory monitoring of anticoagulants. This review presents the performance characteristics of the Anti-Factor Xa assays (measuring Factor Xa inhibition by drugs), which are available for measuring Direct Factor Xa Inhibitors in plasma, and show good compliance of the results with the reference LC:MS method (which measures the mass of Direct Factor Xa Inhibitors). We also present the preparation and validation of drug specific plasma calibrators and controls which are requested for drug measurements. These assays are convenient and practical laboratory tools which can be used in any laboratory setting, and meet the requirements of regulatory bodies for making smart, quantitative, sensitive, accurate and ease of use assays for measuring DOACs when needed. The manuscript focuses mainly on the following areas of current interest: interference in coagulation assays; anti-Xa laboratory methods; development of calibrators and controls for DiXaIs; method validation and comparison with reference techniques (LC:MS); regulatory requirements and method registrations; newer clinical applications and experience on DiXaIs with Anti-Xa assays, and future perspectives.
Hyphen BioMed, Sysmex Group, Neuville sur Oise, France. Electronic address: jamiral@hyphen-biomed.com.
Jean
J
Amiral
Hyphen BioMed, Sysmex Group, Neuville sur Oise, France.
Claire
C
Dunois
Hyphen BioMed, Sysmex Group, Neuville sur Oise, France.
Cédric
C
Amiral
International Consultancy in Blood Components Quality/Safety Improvement, Audit/Inspection and DDR Strategies, London, UK. Electronic address: jseghatchian@btopenworld.com.
Jerard
J
Seghatchian
D001681:Biological Assay / Q000379:methods*; D001780:Blood Coagulation Tests / Q000379:methods; D015951:Factor Xa / Q000378:metabolism*; D065427:Factor Xa Inhibitors / Q000097:blood*; D006801:Humans
D065427:Factor Xa Inhibitors; D015951:Factor Xa
Anticoagulant therapy; Bleeding risk; Chromogenic anti-Factor Xa assay; Direct Factor Xa inhibitors (DiXaIs); Laboratory assays